Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: Contrave, naltrexone hydrochloride/bupropion hydrochloride, naltrexone HCl/bupropion HCl, naltrexone-bupropion extended-release
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
Naltrexone/bupropion is an oral extended-release tablet formulation containing the opioid antagonist naltrexone and the aminoketone antidepressant bupropion. U.S. labeling indicates use with a reduced-calorie diet and increased physical activity for long-term weight reduction and maintenance in adults with obesity or adults with overweight plus at least one weight-related comorbid condition. The exact neurochemical basis of the weight-loss effect is not fully understood; labeling describes effects involving hypothalamic appetite-regulation pathways and mesolimbic reward pathways.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
The FDA-approved strength is 8 mg naltrexone hydrochloride/90 mg bupropion hydrochloride per extended-release tablet. The labeled dose-escalation regimen progresses over four weeks to a maximum of four tablets per day, divided into morning and evening doses; this is recorded here as regulatory reference information, not individualized dosing guidance. Tablets should be swallowed whole and not cut, chewed, or crushed. The product should not be taken with high-fat meals because systemic exposure to both components increases. Coadministration with other bupropion-containing products is contraindicated, and coadministration with other naltrexone-containing products is not recommended. The cardiovascular morbidity and mortality effect has not been established. Initial U.S. approval was in 2014; the FDA label used for this record was revised in November 2025.
Supplementary research context only. Not medical advice or a treatment recommendation.
FDA NDA 200063; RxCUI 1551468 for naltrexone HCl 8 mg/bupropion HCl 90 mg 12-hour extended-release oral tablet; RxCUI 1551474 for Contrave 8 mg/90 mg 12-hour extended-release oral tablet; NDC 51267-890-07 and 51267-890-99; UNII naltrexone hydrochloride Z6375YW9SF; UNII bupropion hydrochloride ZG7E5POY8O
The product is a fixed-dose combination rather than a single discrete molecular entity. Each tablet is a trilayer, film-coated, extended-release tablet containing 8 mg naltrexone hydrochloride and 90 mg bupropion hydrochloride. The current U.S. label identifies oral administration only. Common labeled adverse reactions include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea. Important labeled risks include seizures, increases in blood pressure or heart rate, hepatotoxicity, and suicidal thoughts or behaviors associated with the bupropion component.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.